Clinical Trials Directory

Trials / Unknown

UnknownNCT03457233

The Impact of Body Weight on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles

The Impact of Overweight and Obesity on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
185 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
Female
Age
20 Years – 44 Years
Healthy volunteers
Not accepted

Summary

Induction of ovulation cycle: 1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu. 2. GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration 3. Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans vaginal probe (mindrayDP-5)to assess the ovarian response till the mature follicles reach18-20mm when hCG administration 10000 IU is given.Serum E2 level is done on day of HCG trigger. 4. Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG injection 5. Progesterone vaginal tablets (Prontogest,IBSA) are administrated 400mg twice daily as luteal support from the day of oocytes retrieval. 6. Ultrasound -guided fresh embryo transfer is performed on day 2 or 3 after fertilization. 7. Serum hCG assessment to detect pregnancy is performed at 14 days after embryo transfer .if positive(chemical pregnancy) ,women undergo trans -vaginal ultrasonography 2 weeks after, to confirm fetal pulsations as well as number of gestational sacs (clinical pregnancy). 8. The implantation rate is calculated as the number of viable embryos divided by the number of transferred embryos multiplied by 100

Detailed description

Induction of ovulation cycle: 1. Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration(choriomon,IBSA10000IU) with starting dose 300 to 450iu. 2. GNRH antagonist (cetrorelix 0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration 3. Ovarian ultrasound scans were performed using a 5.0-9.0 MHZ multi frequency trans vaginal probe (mindrayDP-5)to assess the ovarian response till the mature follicles reach18-20mm when hCG administration 10000 IU is given.Serum E2 level is done on day of HCG trigger. 4. Trans vaginal ultrasound-guided oocyte retrieval is performed 34-36 hours after hCG injection 5. Progesterone vaginal tablets (Prontogest,IBSA) are administrated 400mg twice daily as luteal support from the day of oocytes retrieval. 6. Ultrasound -guided fresh embryo transfer is performed on day 2 or 3 after fertilization. 7. Serum hCG assessment to detect pregnancy is performed at 14 days after embryo transfer .if positive(chemical pregnancy) ,women undergo trans -vaginal ultrasonography 2 weeks after, to confirm fetal pulsations as well as number of gestational sacs (clinical pregnancy). 8. The implantation rate is calculated as the number of viable embryos divided by the number of transferred embryos multiplied by 100

Conditions

Interventions

TypeNameDescription
DRUGGonadotropins1\) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
DRUGGNRH antagonistcetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
DRUGHuman chorionic gonadotropin Chorimon10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
DRUGNatural progesterone400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing

Timeline

Start date
2015-01-03
Primary completion
2018-03-01
Completion
2018-03-01
First posted
2018-03-07
Last updated
2018-03-07

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03457233. Inclusion in this directory is not an endorsement.